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ABSTRACT
Nonmyeloablative allogeneic peripheral blood progenitor cell transplantation with low-dose total body irra-
diation (TBI; 200 cGy) plus fludarabine followed by cyclosporine and mycophenolate mofetil results in modest
graft rejection rates. Acute and chronic graft-versus-host diseases (GVHD) are also seen and may not differ
substantially from those that occur after fully ablative transplantation. Adding antithymocyte globulin (ATG)
to pretransplant conditioning produces substantial immunosuppression. Because of its persistence in the
circulation, ATG can achieve in vivo T-cell depletion. Twenty-five patients who were not eligible for conven-
tional fully ablative allogeneic stem cell transplantation by virtue of age or comorbidities underwent nonmy-
eloablative allogeneic transplantation with ATG 15 mg/kg/d days 4 to 1, TBI 200 cGy on a single fraction
on day 5, and fludarabine 30 mg/m2/d on days 4 to 2. Oral mycophenolate mofetil 15 mg/kg every 12
hours and cyclosporine 6 mg/kg every 12 hours were started on day 5. Grafts were unmanipulated peripheral
blood progenitor cells mobilized with filgrastim 10 g/kg/d and collected on day 5. The median age of the
recipients was 57 years (range, 30-67 years); diagnoses were non-Hodgkin lymphoma (n  11), acute myeloid
leukemia (n  6), multiple myeloma (n  3), acute lymphoblastic leukemia (n  2), severe aplastic anemia (n 
1), paroxysmal nocturnal hemoglobinuria (n  1), and myelodysplastic syndrome (n  1). The median CD34
and CD3 contents of the grafts were 7.6  106/kg and 1.6  108/kg, respectively. Five patients received
voluntary unrelated donor grafts. Three patients, 2 with voluntary unrelated donor grafts and 1 with a sib
donor, received a 1 antigen–mismatched graft. The rest were fully matched. Twenty-two of 25 patients were
evaluable for chimerism. Sixteen had >95% donor chimerism. Four patients displayed 80% to 90% donor
chimerism, 1 displayed 78%, and 1 displayed 64%. Eleven patients relapsed with their original disease. One
patient rejected the graft at 180 days. The median hospital stay was 27 days. Complications included GVHD
in 6 patients (3 patients had grade I or II GVHD of skin and liver, and 3 patients had grade III or IV GVHD
of liver and gut). Two of the patients with GVHD had mismatched grafts. Transplant-related toxicity was seen
in 4 patients and infection in 5 patients. The median length of follow-up was 162 days (range, 17-854 days).
Complete remissions were seen in 10 patients. Four patients remained in complete response (CR) at 280 to 595
days. One patient relapsed with non-Hodgkin lymphoma after a CR of 728 days. Of the 25 patients, 16 died (6
of relapsed disease, 4 of GVHD, 3 of infection, and 3 of transplant-related toxicity) and 9 are alive (6 with
CR—2 of them after donor leukocyte infusion—and 3 with relapsed disease). The addition of ATG to low-dose
TBI and fludarabine nonmyeloablative conditioning was well tolerated and resulted in >80% donor engraft-
ment in this small cohort. As in other series of truly nonmyeloablative transplantation, a high rate of relapse
was observed. Donor engraftment may be facilitated by the addition of ATG to low-dose TBI and fludarabine
conditioning.
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INTRODUCTION
Nonmyeloablative allogeneic stem cell transplan-
tation (NST) has extended the beneﬁt of the graft-
versus-tumor effect to patients who are not candidates
for fully ablative stem cell transplantations by virtue of
their age or existing comorbidities. Although peri-
transplantation morbidity and toxicities are markedly
decreased, NSTs are fraught with many of the same
difﬁculties as fully ablative stem cell transplantations.
These include graft-versus-host disease (GVHD), in-
fectious complications, and a somewhat increased rate
of graft rejection and disease relapse. The observation
that full ablation is not necessary for engraftment has
led to the development of numerous trials aimed at
minimizing disease relapse, graft rejection, and
GVHD. Here we present an attempt to minimize
graft rejection and GVHD by in vivo T-cell depletion
by adding horse-derived antithymocyte globulin
(ATG) to a well-established preparative regimen
based on low-dose total body irradiation (TBI) and
ﬂudarabine.
The use of ATG in the setting of allogeneic trans-
plant conditioning is well established. ATG has been
used for the dual purpose of host immunosuppression
and of in vivo T-cell depletion [1]. Its efﬁcacy in
preventing graft rejection is well established, and it is
considered a crucial component in most mismatched
transplantation regimens. Its role in the prevention of
GVHD is more controversial. Studies that support its
use for this purpose [2] and others that found no role
for a T-cell depletion approach [3] have been pub-
lished. In the setting of nonmyeloablative transplan-
tation, these issues remain largely speculative. We
enrolled 25 patients in a single-arm phase I/II study in
which a well-described nonmyeloablative condition-
ing regimen was modiﬁed to include horse-derived
ATG.
MATERIALS AND METHODS
Patients and Conditioning
Twenty-ﬁve patients underwent nonmyeloablative
conditioning and allogeneic transplantation between
June 1999 and January 2002 under an institutional
review board–approved research protocol. To partic-
ipate in the trial, patients had to have an indication for
allogeneic transplantation but not be eligible for full
ablation because of age, comorbidities, or preceding
autologous stem cell transplantation (ASCT). In ad-
dition, patients had to have an HLA-matched or 1
antigen–mismatched related or unrelated donor.
Conditioning consisted of low-dose TBI (200 cGy
in a single fraction) given on day 5. This modiﬁca-
tion was made to avoid the potential for side effects of
ATG hampering the delivery of TBI. Treatment was
administered as follows: ATG (Atgam; Pharmacia-
UpJohn, Kalamazoo, MI), 15 mg/kg/d  4 doses on
days 4 to 1 intravenously (IV) over 6 hours; TBI,
200 cGy on a single fraction on day 5; ﬂudarabine
(Fludara; Berlex Laboratories, Inc., Richmond, CA),
30 mg/m2/d  3 doses on days 4 to 2 IV over 30
minutes; oral mycophenolate mofetil (CellCept;
Roche Laboratories Inc., Nutley, NJ), 15 mg/kg every
12 hours; and cyclosporine (Neoral; Novartis Phar-
maceuticals Corporation, East Hanover, NJ), 6 mg/kg
every 12 hours starting on day 5. In the absence of
GVHD, disease relapse, or loss of chimerism, cyclo-
sporine taper was initiated at day 120, and mycophe-
nolate mofetil taper was initiated at day 180.
Priming and Transplantation
Donors, after signing informed consent, received
5 daily doses of 10 g/kg of ﬁlgrastim (Neupogen;
Amgen, Inc., Thousand Oaks, CA) subcutaneously
before peripheral blood stem cell collection. The tar-
get collection was 2.5  106 CD34 cells per kilo-
gram of recipient body weight. The volume processed
was generally 3 times the total blood volume of the
donor. For bone marrow grafts, harvests were per-
formed by conventional technique. No manipulation
was performed on the product except for plasma or
red cell depletion as required for ABO incompatibil-
ity.
Supportive Therapy and Donor Leukocyte Infusion
IV gamma globulin 0.5 g/kg was given every 4
weeks starting on day 1. Other supportive care in-
cluded gut decontamination with oral ciproﬂoxacin,
oral ﬂuconazole, IV acyclovir, and Pneumocystitis cari-
nii pneumonia prophylaxis. No routine growth factors
were used. Prophylactic transfusions of platelets were
given for a platelet count of 10  109/L if there was
no bleeding and 50  109/L if bleeding occurred.
Routine chimerism studies were scheduled at days
30, 90, 180, and 365 after transplantation. Donor
leukocyte infusions (DLIs) were given for donor chi-
merism 50% of total nucleated cells in peripheral
blood or bone marrow or disease relapse. To receive
DLI, patients had to have no GVHD off immunosup-
pression. DLI were adjusted to contain approximately
1  108 CD3 lymphocytes per kilogram of recipient
body weight. DLI could be repeated a maximum of 3
times, 12 weeks apart.
Engraftment, GVHD, Hospitalization, and Disease
Relapse
The International Bone Marrow Transplant Reg-
istry deﬁnitions for engraftment of neutrophils and
platelets were used. GVHD grading was performed as
described previously [4]. Donor chimerism was deter-
mined by conventional cytogenetics, ﬂuorescence in
C. Grosskreutz et al.
454
situ hybridization, variable number tandem repeats
analysis, or a combination of these.
RESULTS
Patients
Patient characteristics are summarized in Table 1.
Of the 25 patients, 17 were 55 years or older, and
another 4 were 50 to 54 years old. Ten patients had
previous ASCT. Fourteen patients had signiﬁcant co-
morbid conditions. The diagnoses in the patients were
as follows. Eleven patients had non-Hodgkin lym-
phoma (NHL). Of those, 5 patients had relapsed and
5 had refractory disease. One patient with mantle cell
lymphoma had a partial response after chemotherapy.
Six patients had acute myeloid leukemia (AML).
Three had de novo and 3 secondary AML. Two pa-
tients were in complete remission (CR) 2, 1 was in
CR1, 1 was refractory, 1 was in relapse, and the other
was untreated. Two patients had acute lymphoblastic
leukemia, and both were in CR2. Three patients had
multiple myeloma. Two of them had relapsed after
ASCT. The third was in CR after chemotherapy and
had end-stage renal disease. One patient had severe
aplastic anemia after receiving conventional chemo-
therapy for ovarian cancer. One patient had paroxys-
mal nocturnal hemoglobinuria with red cell transfu-
sion requirement, active viral hepatitis, and severe
iron deposition in the liver. One patient had myelo-
dysplastic syndrome in transformation to AML and
was previously untreated.
Donors and Grafts
The characteristics of the donors and grafts are
summarized on Table 2. Twenty patients received
allografts from siblings. One of them was mismatched
for 1 antigen at the B locus. The others were fully
matched. Five patients received unrelated donor stem
cells. Two had single-allele mismatches, and 3 had 10
antigen–matched donors.
Five patients received grafts with a CD34 cell per
kilogram content of 2.5  106. One patient with
mantle cell NHL died on day 27 after counts had
recovered, and 1 with severe aplastic anemia died on
day 17 before engraftment occurred. The other 3
patients developed full donor chimerism. Six patients
underwent transplantation with 8  106 CD34 cells
per kilogram. One of them developed fatal gut and
liver GVHD.
Engraftment
Of the 25 patients, 19 patients (76%) engrafted
with a neutrophil count 500/L at a median of 12
days (range, 6 to 24 days); 6 patients (24%) never had
neutrophil counts below 500/L. In 17 patients
(68%), platelet engraftment occurred at a median of
12 days (range, 3 to 27 days); 8 patients (32%) never
had platelet counts below 20000/L.
Chimerism
Chimerism, GVHD, and outcome data are sum-
marized in Table 3. The highest chimerism found was
at a median of 37 days after transplantation. Donor
engraftment could be assessed in 22 patients who were
alive for 29 days. Of these, 11 were veriﬁed by
ﬂuorescence in situ hybridization analysis with X/Y
probes, and 11 were veriﬁed by variable number tan-
dem repeats analyses in bone marrow and peripheral
blood nucleated cells. Thirteen patients achieved full
Table 1. Clinical Characteristics of the 25 Patients
Variable Data
N 25
Median age, y (range) 57 (30-67)
Sex (M:F) 15:10
Diagnosis, n (%)
NHL 11 (44)
AML 6 (24)
ALL 2 (8)
MM 3 (12)
SAA 1 (4)
PNH 1 (4)
MDS 1 (4)
Disease status, n (%)
Early 6 (24)
Late 19 (76)
Prior ASCT, n (%) 10 (40)
KPS, median (range) 50 (30-100)
KPS >80, n (%) 12 (48)
KPS 50-80, n (%) 9 (36)
KPS <50, n (%) 4 (16)
NHL indicates non-Hodgkin lymphoma; AML, acute myeloid
leukemia; ALL, acute lymphoblastic leukemia; MM, multiple my-
eloma; SAA, severe aplastic anemia; PNH, paroxysmal nocturnal
hemoglobinuria; MDS, myelodysplastic syndrome; ASCT, autolo-
gous stem cell transplantation; KPS, Karnofsky performance score.
Table 2. Characteristics of the Donors and Grafts
Variable Data
Median age, y (range) 57 (30-67)
Related: VUD 20:5
HLA matching, n (%)
Sib match 19 (76)
VUD match 3 (12)
Sib mm 1 (4)
VUD mm 2 (8)
Sex donor 3 recipient, n (%)
M 3 M 6 (24)
F 3 F 6 (24)
M 3 F 4 (16)
F 3 M 9 (36)
CD34/kg ( 106), mean (range) 7.6 (0.5-41.9)
CD3/kg ( 108), mean (range) 1.64 (0.6-4.8)
VUD indicates voluntary unrelated donor; mm, mismatch.
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(98%) donor chimerism; of these 6 are alive, and 4
are in CR.
Seventeen patients have lost their graft, not en-
grafted, or died peritransplantation without documen-
tation of stable donor engraftment. Ten patients lost
their graft concurrently with progression or relapse of
their original disease. One patient with NHL is alive
in CR with stable chimerism (50% donor and 50%
host cells), and 1 patient with multiple myeloma be-
came 100% host but remains in CR. Two patients
died on days 17 and 19 from central nervous system
(CNS) toxicity and sepsis, respectively, without doc-
umentation of engraftment. Three other patients had
early evidence of donor chimerism (2 patients at 100%
and 1 patient at 64%) but died on days 27, 28, and 29
of acute respiratory distress syndrome (ﬁrst patient)
and GVHD (last 2 patients) without documentation of
stable chimerism.
Of the 13 patients who developed full chimerism,
5 experienced a partial or complete loss of donor cells.
Two patients lost the graft but had durable remissions
of their disease. One partially (50% donor 482 days
after transplantation) and the other completely dis-
played a graft loss 1 year after transplantation.
DLIs were given to 8 patients. Infusions were
administered at a median of 160 days (range, 80-792
days) after transplantation. One patient received 1
dose of DLI, achieved CR, and developed mild skin
GVHD after DLI. One patient received 1 dose of
DLI with good response but died of an infectious
complication later on; 2 patients received 1 DLI but
died of progressive disease. Three patients received 2
doses of DLI. Two of them are alive in CR, and 1 died
of relapsed disease. One patient received 3 doses of
DLI and is alive with relapse.
Graft-versus-Host Disease
Six patients (24%) developed acute GVHD. In 2
(8%), GVHD of skin and liver was modest (grade I or
II). Four (16%) other patients had severe grade III or
IV liver and gut GVHD. Overall, 3 of the patients
with GVHD had mismatched grafts. Four patients
died with acute GVHD: 1 with refractory NHL and a
matched sibling donor, 1 with paroxysmal nocturnal
hemoglobinuria and a matched voluntary unrelated
donor graft, 1 with acute lymphoblastic leukemia and
a mismatched sibling, and 1 with refractory NHL and
a mismatched voluntary unrelated donor graft.
Two patients (13%) of the 15 who survived be-
yond day 100 developed chronic GVHD. One patient
had limited skin involvement. The other had extensive
chronic GVHD that involved the gastrointestinal
tract, liver, and skin. Both patients recovered com-
pletely with further immunosuppressive treatment.
Infections
Four patients had fatal infectious complications.
One patient developed Staphylococcus aureus infection
17 days after transplantation and died as a result of it.
Two other patients also died with suspected infection
but with negative cultures at 40 and 96 days after
transplantation. One of them had severe GVHD. One
patient developed sepsis caused by Klebsiella organisms
492 days after transplantation and died. Only 1 patient
developed cytomegalovirus disease consisting of coli-
tis 1 year after transplantation. This resolved with
antiviral therapy.
Transplant Toxicities
Three patients died as a result of transplant-re-
lated toxicity: 1 with veno-occlusive disease (75 days
after transplantation), 1 with neurotoxicity (19 days
after transplantation), and another with acute respira-
tory distress syndrome (27 days after transplantation).
As in other ablative and nonablative regimens that use
horse-derived ATG, the most common toxicities at-
tributable to this agent were rigors and fever. No
patient developed anaphylaxis. One patient developed
Table 3. Complications and Outcomes
Diagnosis
% Donor,
(day) GVH TRT Infections Outcome
ALL N/A G, L D
AML 100 (19) Y Rel/D
NHL 95.90 [14] Rel/D
SAA N/A Y D
NHL 64 [14] G, L, S Y D
NHL 100 [59] S Rel/CR
NHL 95 [84] R
AML 100 [43] R
MM 90 [30] CNS Y D
MM 85.5 [16] CR
MDS 100 [43] R
NHL 100 [42] L, S Y D
ALL 98 [30] L D
NHL 87 [49] Rel/CR
AML 78 [33] Rel/D
NHL 100 [20] Lung D
MM N/A CNS D
AML 97.6 [21] Rel/D
AML 85 [50] Rel/D
PNH 100 [20] S, L, G D
NHL 99.9 [105] CR
NHL 99.8 [63] CR
NHL 100 [87] Rel/D
NHL 100 [54] G D
AML 100 [31] CR
S indicates skin; L, liver; G, gut, Rel, relapse; D, dead; Y, yes;
TRT, transplant-related toxicity; (day), day of highest chimerism;
GVH, graft versus host; ALL, acute lymphoblastic leukemia; AML,
acute myeloid leukemia; NHL, non-Hodgkin lymphoma; SAA, se-
vere aplastic anemia; MM, multiple myeloma; MDS, myelodysplas-
tic syndrome, PNH, paraoxysmal nocturnal hemoglobinuria; N/A,
not applicable; CNS, central nervous system; CR, complete re-
sponse.
C. Grosskreutz et al.
456
a serum-sickness type of syndrome that was responsive
to corticosteroids. In no case did the administration of
ATG lead to severe toxicities or to alterations of the
conditioning regimen.
Two patients developed CNS toxicities with pro-
gressive changes in mental status that progressed to
stupor, without focal signs and with normal imaging
brain studies. In both cases, ﬂudarabine toxicity was
suspected.
Disease Outcomes
The median follow-up of patients in this study was
162 days (range, 12-854 days). The median time of
death after transplantation was 84 days. Ten patients
(40%) died before day 100.
Eleven patients have relapsed. Five of them had
NHL, 3 were treated with DLI and are alive and in
CR, and 2 died with relapsed NHL. Five patients had
AML, 4 of whom relapsed between 3 and 6 months
after transplantation; they were treated with DLI,
with no response. Three of them died in relapse, 1
died secondary to an infectious complication, and the
other was in CR for a year and is now relapsed. One
patient with myelodysplastic syndrome relapsed 1 year
after transplantation, received 3 doses of DLI with no
response, and is alive in relapse.
Six patients are alive in CR (1 with AML, 4 with
NHL, and 1 with multiple myeloma); 4 of them never
showed any evidence of relapse (from 280 to 595
days). The Kaplan-Meier curves for event-free and
overall survival are shown in Figures 1 and 2.
DISCUSSION
In this study we used a well-established agent for
inducing immunosuppression together with a previ-
ously described nonmyeloablative regimen to condi-
tion patients before allografting. The doses of the TBI
and ﬂudarabine for NST were identical to those pre-
viously reported [5]. However, the timing of the TBI
was changed to avoid overlapping its administration
with the rare but occasionally serious side effects of
ATG. As in most pilot studies of NST, the patients
enrolled in this study were not candidates for conven-
tional allotransplantation. Several of them were of
advanced age or had a previous ASCT. Thus, this
cohort was likely to display a high rate of transplant
complications, including GVHD. The age of the re-
cipients (median, 57 years) was also likely to result in
a higher than expected rate of GVHD. In addition,
20% of the patients received stem cells from an un-
related donor and 15% from mismatched donors,
both additional risks for developing GVHD and post-
transplant complications.
In our cohort, the administration of ATG to-
gether with low-dose TBI and ﬂudarabine resulted in
80% donor engraftment in 90% of evaluable pa-
tients. Only 2 patients had a partial or full graft rejec-
tion in the absence of disease relapse. Both patients
had persistent remissions despite graft loss. This phe-
nomenon has been previously described [6]. One of
the patients in whom this was veriﬁed had refractory
disease at the time of transplantation. The other pa-
tient, despite displaying a complete loss of the graft,
later underwent a living related kidney transplantation
from the same donor and showed normal renal func-
tion with no evidence of rejection (unpublished data,
Isola and Bromberg, 1999). All other patients who
developed loss of the graft did so at the time of disease
relapse.
A low graft rejection in 87 patients treated with
the TBI/ﬂudarabine regimen without ATG has been
reported recently [7].
It is interesting to note that 3 patients received
stem cells from partially mismatched donors. Two
mismatched donors were also unrelated and carried
allele mismatches at the DR B1 and A loci. A third
donor was a sibling who differed from his recipient at
1 of the B loci. In 2 cases, the full donor type was
veriﬁed. The other patient had 64% donor chimerism.
Figure 1. Kaplan-Meier event-free survival (EFS) curve. Tx indi-
cates transplantation.
Figure 2. Kaplan-Meier overall survival curve. Tx indicates trans-
plantation.
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These cases suggest that the combination of ATG and
low-dose TBI plus ﬂudarabine may be sufﬁcient con-
ditioning to permit the engraftment of unmanipulated
mismatched allografts. However, because 2 of these 3
patients also developed signiﬁcant GVHD, manipula-
tions of the graft may be needed to address this con-
cern.
The cohort that underwent transplantation in this
study included patients with serious comorbidities and
also those with preceding ASCT. Two of the patients
developed CNS manifestations suspected to be related
to ﬂudarabine administration. One of the patients was
receiving chronic hemodialysis and received an ad-
justed dose of ﬂudarabine. Both patients carried a
diagnosis of multiple myeloma and had undergone
previous ASCT. Because there are now encouraging
reports on the use of intermediate-dose melphalan
[8,9] for NST after ASCT in the setting of multiple
myeloma, this regimen may be preferable.
Fatal GVHD occurred in 4 patients. One of them
had an unrelated donor who was matched by high-
resolution DNA typing at A, B, C, DR, and DQ. This
patient had a severe form of paroxysmal nocturnal
hemoglobinuria with massive, persistent hemolysis
that required chronic packed red blood cell transfu-
sion support and resulted in iron overload. Of interest,
the hemolysis completely resolved within 2 weeks of
the NST. Eventually the patient developed grade IV
GVHD of the intestine and liver and did not respond
to aggressive immunotherapy. The second patient
with fatal GVHD had a follicular lymphoma with
aggressive clinical behavior that was refractory to nu-
merous chemotherapy and monoclonal antibody reg-
imens. His donor was a multiparous HLA-identical
sister. Again, immediately after the NST, a complete
resolution of the disease was veriﬁed, and the patient
was rapidly discharged with full donor chimerism. On
day 93, the patient developed grade IV gut GVHD
and died despite aggressive treatment.
Horse-derived ATG has been widely used to pro-
vide immunosuppression in the setting of allogeneic
transplantation with related [2], unrelated [10], and
cord blood transplantation [11]. ATG has been com-
bined with both fully ablative [10] and NST condi-
tioning regimens [12]. In all these settings, it seems to
contribute to graft tolerance without adding myelo-
suppression or increasing the toxicities typical of ra-
diation and chemotherapy. Because it operates on T
cells via a different mechanism than nucleoside ana-
logs and calcineurin inhibitors, it seems ideal for im-
munosuppression in the setting of NST. In addition,
horse-derived ATG has a half-life in the peripheral
circulation of 1.5 to 12 days (median, 5.7 days; unpub-
lished data provided by Pharmacia-Upjohn). There-
fore, is logical to predict that it may exert an inhibitory
or lympholytic effect [13] on the postthymic T cells
infused with allografts that are presumed to be respon-
sible for the development of GVHD. This effect has
been previously explored in the setting of fully ablative
transplantations [14], and results remain somewhat
controversial. In our own series, the addition of ATG
seemed to decrease the incidence of grade I or II
GVHD compared with a similar regimen without
ATG but did not seem to change the incidence of
severe GVHD [7]. These results need to be inter-
preted with caution because the cohorts are limited in
size and were treated at different institutions.
This pilot study was not designed to identify a
dose of ATG that would maximize engraftment or
reduce the incidence of disease relapse and infections.
For that purpose, a properly powered study of a single
disease would need to be undertaken.
Other agents, such as alemtuzumab (Campath;
Berlex Laboratories, Richmond, CA) 1H, have also
been used for the same purpose with a similar ratio-
nale [15]. The use of alemtuzumab 1H is associated
with only a 4% incidence of acute GVHD in HLA-
identical sibling transplantation [15] and with a 24%
incidence in recipients of unrelated donors [16].
Again, as with ATG, studies addressing the ideal dose
of Campath 1H in the setting of allotransplantation
are lacking.
In conclusion, the addition of ATG to low-dose
TBI and ﬂudarabine seems well tolerated and resulted
in 80% donor engraftment in 90% of all evaluable
patients of this small cohort. Although graft rejection
was completely avoided, severe GVHD did occur de-
spite the addition of ATG. ATG may still help to
decrease the rate or severity of GVHD in this setting.
Because of the limited number of patients and their
characteristics, this cannot be ascertained. The addi-
tion of ATG could have hampered the graft-versus-
leukemia effect. Nine patients with 100 days of dis-
ease-free survival who underwent transplantation and
had relapsed or refractory disease showed dramatic
graft-versus-leukemia responses. This conﬁrms that
ATG does not completely obliterate the ability of the
graft to exert an antitumor effect. As in the case of
GVHD, quantitative differences in the extent and rate
of effective graft-versus-leukemia effects due to ATG
would require a different study design.
ACKNOWLEDGMENTS
The authors thank Ronald Egan for expert assis-
tance with data management and Christine Keaveny
for protocol management.
REFERENCES
1. Ash RC, Horowitz MM, Gale RP, et al. Bone marrow trans-
plantation from related donors other than HLA-identical sib-
lings: effect of T cell depletion. Bone Marrow Transplant. 1991;
7:443-452.
C. Grosskreutz et al.
458
2. Kroger N, Zabelina T, KrugerW, et al. In vivo T cell depletion
with pretransplant anti-thymocyte globulin reduces graft-ver-
sus-host disease without increasing relapse in good risk myeloid
leukemia patients after stem cell transplantation from matched
related donors. Bone Marrow Transplant. 2002;29:683-689.
3. Doney KC, Weiden PL, Storb R, et al. Failure of early admin-
istration of antithymocyte globulin to lessen graft-versus-host
disease in human allogeneic marrow transplant recipients.
Transplantation. 1981;31:141-143.
4. Vogelsang GBAcute graft-versus-host disease following mar-
row transplantationMarrow Transplantation Reviews, 1991-
1994Biology and Clinical Practice of Hematopoietic Trans-
plantationIn: , Sullivan KM, Koppa SD Charlottesville VA,
Kluge Carden Jennings, 1995, 150-153
5. Storb RF, Champlin R, Riddell SR, et al. Non-myeloablative
transplants for malignant disease. Hematology (Am Soc Hema-
tol Educ Program). 2001:375-391.
6. Spitzer TR, Delmonico F, Tolkoff-Rubin N, et al. Combined
histocompatibility leukocyte antigen-matched donor bone mar-
row and renal transplantation for multiple myeloma with end
stage renal disease: the induction of allograft tolerance through
mixed lymphohematopoietic chimerism. Transplantation. 1999;
68:480-484.
7. Sandmaier B, Maloney D, Gooley T, et al. Nonmyeloablative
hematopoietic stem cell transplants (HSCT) from HLA-
matched related donors for patients with hematologic malig-
nancies: clinical results of a TBI-based conditioning regimen-
Fred Hutchinson Cancer Research Center, Seattle, WA;
University of Washington, Seattle, WA; University of Lipzig,
Germany; Stanford University, Stanford, CA; City of Hope
National Medical Center, Duarte, CA; VA Medical Center,
Seattle, WA; Baylor University, Dallas, TX; University of
Torino, Italy; University of Colorado, Denver, CO. Blood 2001;
98:742a (abstr.)
8. Kroger N, Schwerdtfeger R, Kiehl M, et al. Autologous stem
cell transplantation followed by a dose-reduced allograft in-
duces high complete remission rate in multiple myeloma. Blood.
2002;100:755-760.
9. Kroger N, Sayer HG, Schwerdtfeger R, et al. Unrelated stem
cell transplantation in multiple myeloma after a reduced-inten-
sity conditioning with pretransplantation antithymocyte glob-
ulin is highly effective with low transplantation-related mortal-
ity. Blood. 2002;100:3919-3924.
10. Kroger N, Zabelina T, Kruger W, et al. Anti-thymocyte-glob-
ulin as part of the preparative regimen prevents graft failure and
severe graft versus host disease (GvHD) in allogeneic stem cell
transplantation from unrelated donors. Ann Hematol. 2001;80:
209-215.
11. Thomson BG, Robertson KA, Gowan D, et al. Analysis of
engraftment, graft-versus-host disease, and immune recovery
following unrelated donor cord blood transplantation. Blood.
2000;96:2703-2711.
12. Basara N, Roemer E, Kraut L, et al. Reduced intensity prepar-
ative regimens for allogeneic hematopoietic stem cell transplan-
tation: a single center experience. Bone Marrow Transplant.
2002;30:651-659.
13. Bonnefoy-Berard N, Verrier B, Vincent C, et al. Inhibition of
CD25 (IL-2R alpha) expression and T-cell proliferation by
polyclonal anti-thymocyte globulins. Immunology. 1992;77:61-
67.
14. Rodt H, Kolb HJ, Netzel B, et al. Effect of anti-T-cell globulin
on GVHD in leukemic patients treated with BMT. Transplant
Proc. 1981;13(1 part 1):257-261.
15. Hale G, Jacobs P, Wood L, et al. CD52 antibodies for preven-
tion of graft-versus-host disease and graft rejection following
transplantation of allogeneic peripheral blood stem cells. Bone
Marrow Transplant. 2000;26:69-76.
16. Marks DI, Bird JM, Vettenranta K, et al. T cell-depleted
unrelated donor bone marrow transplantation for acute my-
eloid leukemia. Biol Blood Marrow Transplant. 2000;6:646-653.
ATG for Nonmyeloablative Transplantation
459BB&MT
